SPOTLIGHT: Regulus gets CEO

Alnylam Pharmaceuticals and Isis Pharmaceuticals have named Kleanthis G. Xanthopoulos as president and chief executive of their joint venture--Regulus Therapeutics. Xanthopoulos is the former CEO of Anadys. Release

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.